STOCKS TELEGRAPH

Tag: VYNT stock

  • Vyant Bio Inc. (VYNT) stock’s Cascade Continues into the After Hours. Any Reason?

    Vyant Bio Inc. (VYNT) stock’s Cascade Continues into the After Hours. Any Reason?

    On January 21, Vyant Bio Inc. (VYNT) stock fell by a further 14.17% in the after-market session.

    In the regular trading session, the stock lost 6.25% at its close of $1.20. This downtrend continued into the after hours, as VYNT plunged further down to $1.03. Hence, the stock has gone well below its 52-week low of $1.1950.

    The advanced biotechnology drug discovery company, Vyant Bio Inc. was founded in 1999. Currently, its 28.99 million outstanding shares trade at a market capitalization of $34.79 million. Furthermore, VYNT stock presently stands at a year-to-date loss of 11.11% while it lost 71.50% last year.

    Why VYNT Declined?

    As of recently, there has been no official news, new SEC filing, or an upcoming event in the company’s timeline. Despite this, the VYNT stock has been going up and down, probably due to some social media chatter. While the stock has mainly been in a downtrend, it has also seen occasional slight additions as well.

    On Friday, the stock fell down to a low of $1.20 and closed the session at the same. VYNT stooped well below its 52-week low of $1.1950 in the after-hours as it reached $1.03. Given the new low, the stock might present a good buying opportunity and possibly recover in the next session. But then again, it all depends on how the investors see this low, as the stock has been all but going down.

    Recent Participations

    Recently, the company participated in the H.C. Wainwright Bioconnect Conference which was held from January 10-13, 2022. Moreover, VYNT’s CEO, Jay Roberts, and Chief Scientific Officer, Robert Fremeau discussed key highlights of the company from 2021. In addition, they also provided a business and strategic outlook for 2022.

    Previously, the company also participated in The Benchmark Company Discovery One-on-One Investor Conference on December 02, 2021.

    Before that, the company had presented at the Q4 Investor Summit Micro & Small-Cap Conference in November 2021.

    VYNT’s Q3 2021 Financial Analysis

    On November 11, the company disclosed its financial data for the third quarter of 2021.

    In the third quarter of 2021, the company had total revenues of $1.5 million.

    In addition, the research & development, and selling, general & administrative expenses were $1.2 million and $3.3 million, respectively.

    Further, VYNT ended the quarter with cash and cash equivalents of $23.3 million on September 30, 2021.

  • Vyant Bio, Inc. (VYNT) Stock Undergoes Minor Volatility Ahead of Granting of US Patent for iPSCs

    Vyant Bio, Inc. (VYNT) stock prices were down by 5.22% at the end of the trading day on July 14th, 2021, bringing the price per share down to USD$3.27 at the end of the trading day. Subsequent premarket fluctuations have seen the stock recover by 5.81%, bringing it up to USD$3.46.

    StemoniX Granted US Patent

    July 13th, 2021 saw the company announce that StemoniX, its wholly-owned subsidiary, was issued a US Patent by the United States Patent and Trademark Office (USPTO). The patent is titled “High Throughput Optical Assay of Human Mixed Cell Population Spheroids” and covers a novel approach to the application of human-induced Pluripotent Stem Cells (iPSCs) as an effective tool in the illumination of the biology of complex human cell types, such as those of the central nervous system (CNS).

    Nature of iPSC Platform

    Human iPSC-based, high-throughput platforms that currently exist have lacked reliability and functional consistency. The patent also covers the use of 3D co-cultures of cortical neurons and astrocytes that display spontaneous, rhythmic, and highly synchronized neural activity. This activity can visualized as calcium oscillations on standard, high-throughput fluorescent readers as a platform for CNS-based discovery effects.

    Details of iPSC

    Spontaneous activity and spheroid structure proved to be highly consistent from well-to-well, which is a feature that is lacking in traditional 2D cultures. The technology facilitates a cost-effective method to perform high-throughput drug screening (HTS) in regard to 3D human tissue relevant models that have a higher degree of biological accuracy. This patent marks the third patent granted to StemoniX, with additional applications currently pending across globe.

    Competitive Advantage

    Existing conventional high-throughput drug screening typically makes use of recombinant cell lines that overexpress a drug target of interest. The technology is aimed to deliver the development of relevant cellular disease models that will be used in high-throughput screening. Human iPSCs have been proven to have significant advantages over recombinant cell lines or primary rodent cells that will be used in drug screening. Given that the cells are derived from human donors, human genetic diseases can be modelled more accurately, particularly when used in tandem with modern genome editing techniques.

    Future Outlook for VYNT

    Armed with the promising potential of the patent granted to StemoniX, VYNT is poised to capitalize on the expanded scope of opportunities presented to it. Keen to pioneer their segment of the healthcare system, the company is pushing for the continued development of their innovative technology. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to usher in significant and sustained increases in shareholder value.